Matthew L. Kaplan insider trades: Nuvectis Pharma (NVCT) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Matthew reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 5, 2025 | NVCT | ↑ Buy | 11,000 | $5.84 | $64K | Direct | Nov 6, 2025 (1d) |
| May 12, 2022 | NVCT | ↑ Buy | 3,000 | $16.88 | $51K | Direct | May 16, 2022 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NVCT insiders
Open-market trades in the last 12 months
About Matthew L. Kaplan's insider trades
Matthew L. Kaplan is a director at Nuvectis Pharma (NVCT). Since May 12, 2022, Matthew has reported 2 open-market purchases worth $115K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NVCT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.